Phosphodiesterase‐5 inhibition potentiates cerebrovascular reactivity in chronic traumatic brain injury
Authors:
Open Access
- 7 March 2018
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 5 (4) , 418-428
Abstract
Background: Traumatic cerebrovascular injury (TCVI), a common consequence of traumatic brain injury (TBI), presents an attractive therapeutic target. Because phosphodiesterase‐5 (PDE5) inhibitors potentiate the action of nitric oxide (NO) produced by endothelial cells, they are candidate therapies for TCVI. This study aims to: (1) measure cerebral blood flow (CBF), cerebrovascular reactivity (CVR), and change in CVR after a single dose of sildenafil (ΔCVR) in chronic TBI compared to uninjured controls; (2) examine the safety and tolerability of 8‐week sildenafil administration in chronic symptomatic moderate/severe TBI patients; and as an exploratory aim, (3) assess the effect of an 8‐week course of sildenafil on chronic TBI symptoms.Methods: Forty‐six subjects (31 chronic TBI, 15 matched healthy volunteers) were enrolled. Baseline CBF and CVR before and after administration of sildenafil were measured. Symptomatic TBI subjects then completed an 8‐week double‐blind, placebo‐controlled, crossover trial of sildenafil. A neuropsychological battery and neurobehavioral symptom questionnaires were administered at each study visit.Results: After a single dose of sildenafil, TBI subjects showed a significant increase in global CVR compared to healthy controls (P < 0.001, d = 0.9). Post‐sildenafil CVR maps showed near‐normalization of CVR in many regions where baseline CVR was low, predominantly within areas without structural abnormalities. Sildenafil was well tolerated. Clinical Global Impression (CGI) scale showed a trend toward clinical improvement while on sildenafil treatment.Findings: Single‐dose sildenafil improves regional CVR deficits in chronic TBI patients. CVR and ΔCVR are potential predictive and pharmacodynamic biomarkers of PDE5 inhibitor therapy for TCVI. Sildenafil is a potential therapy for TCVI.Keywords
Funding Information
- Uniformed Services University of the Health Sciences
- National Institutes of Health
This publication has 41 references indexed in Scilit:
- Forebrain-dominant deficit in cerebrovascular reactivity in Alzheimer's diseaseNeurobiology of Aging, 2012
- Neurovascular function in Alzheimer's disease patients and experimental modelsJournal of Cerebral Blood Flow & Metabolism, 2011
- Combinational Therapy Using Hypothermia and the Immunophilin Ligand FK506 to Target Altered Pial Arteriolar Reactivity, Axonal Damage, and Blood–Brain Barrier Dysfunction after Traumatic Brain Injury in RatJournal of Cerebral Blood Flow & Metabolism, 2010
- Intact Memory in TGF-β1 Transgenic Mice Featuring Chronic Cerebrovascular Deficit: Recovery with PioglitazoneJournal of Cerebral Blood Flow & Metabolism, 2010
- The Adverse Pial Arteriolar and Axonal Consequences of Traumatic Brain Injury Complicated by Hypoxia and Their Therapeutic Modulation with Hypothermia in RatJournal of Cerebral Blood Flow & Metabolism, 2009
- On the assessment of cerebrovascular reactivity using hypercapnia BOLD MRINMR in Biomedicine, 2009
- The Long-Term Microvascular and Behavioral Consequences of Experimental Traumatic Brain Injury after Hypothermic InterventionJournal of Neurotrauma, 2009
- Cerebral vascular responsiveness after experimental traumatic brain injury: the beneficial effects of delayed hypothermia combined with superoxide dismutase administrationJournal of Neurosurgery, 2008
- Classification of Traumatic Brain Injury for Targeted TherapiesJournal of Neurotrauma, 2008
- Magnetic Resonance Imaging Investigation of Axonal Remodeling and Angiogenesis after Embolic Stroke in Sildenafil-Treated RatsJournal of Cerebral Blood Flow & Metabolism, 2008